CHAPTER 4: NEUROBLASTOMA DRUGS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Immunotherapy
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injectable
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Online
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Offline
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: NEUROBLASTOMA DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Type
7.2.5.1.2. Market size and forecast, by Route of Administration
7.2.5.1.3. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Type
7.2.5.2.2. Market size and forecast, by Route of Administration
7.2.5.2.3. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Type
7.2.5.3.2. Market size and forecast, by Route of Administration
7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Type
7.3.5.1.2. Market size and forecast, by Route of Administration
7.3.5.1.3. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Type
7.3.5.2.2. Market size and forecast, by Route of Administration
7.3.5.2.3. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Type
7.3.5.3.2. Market size and forecast, by Route of Administration
7.3.5.3.3. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Type
7.3.5.4.2. Market size and forecast, by Route of Administration
7.3.5.4.3. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Type
7.3.5.5.2. Market size and forecast, by Route of Administration
7.3.5.5.3. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Type
7.3.5.6.2. Market size and forecast, by Route of Administration
7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Type
7.4.5.1.2. Market size and forecast, by Route of Administration
7.4.5.1.3. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Type
7.4.5.2.2. Market size and forecast, by Route of Administration
7.4.5.2.3. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Type
7.4.5.3.2. Market size and forecast, by Route of Administration
7.4.5.3.3. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Type
7.4.5.4.2. Market size and forecast, by Route of Administration
7.4.5.4.3. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Type
7.4.5.5.2. Market size and forecast, by Route of Administration
7.4.5.5.3. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Type
7.4.5.6.2. Market size and forecast, by Route of Administration
7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Type
7.5.5.1.2. Market size and forecast, by Route of Administration
7.5.5.1.3. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Type
7.5.5.2.2. Market size and forecast, by Route of Administration
7.5.5.2.3. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Type
7.5.5.3.2. Market size and forecast, by Route of Administration
7.5.5.3.3. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Type
7.5.5.4.2. Market size and forecast, by Route of Administration
7.5.5.4.3. Market size and forecast, by Distribution Channel
List of Tables
Table 01. Global Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 02. Neuroblastoma Drugs Market for Chemotherapy, by Region, 2022-2032 ($Million)
Table 03. Neuroblastoma Drugs Market for Immunotherapy, by Region, 2022-2032 ($Million)
Table 04. Neuroblastoma Drugs Market for Others, by Region, 2022-2032 ($Million)
Table 05. Global Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 06. Neuroblastoma Drugs Market for Oral, by Region, 2022-2032 ($Million)
Table 07. Neuroblastoma Drugs Market for Injectable, by Region, 2022-2032 ($Million)
Table 08. Global Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 09. Neuroblastoma Drugs Market for Online, by Region, 2022-2032 ($Million)
Table 10. Neuroblastoma Drugs Market for Offline, by Region, 2022-2032 ($Million)
Table 11. Neuroblastoma Drugs Market, by Region, 2022-2032 ($Million)
Table 12. North America Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 13. North America Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 14. North America Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 15. North America Neuroblastoma Drugs Market, by Country, 2022-2032 ($Million)
Table 16. U.S. Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 17. U.S. Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 18. U.S. Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 19. Canada Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 20. Canada Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 21. Canada Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 22. Mexico Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 23. Mexico Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 24. Mexico Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 25. Europe Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 26. Europe Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 27. Europe Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 28. Europe Neuroblastoma Drugs Market, by Country, 2022-2032 ($Million)
Table 29. Germany Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 30. Germany Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 31. Germany Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 32. France Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 33. France Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 34. France Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 35. UK Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 36. UK Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 37. UK Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 38. Italy Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 39. Italy Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 40. Italy Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 41. Spain Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 42. Spain Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 43. Spain Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 44. Rest of Europe Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 45. Rest of Europe Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 46. Rest of Europe Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 47. Asia-Pacific Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 48. Asia-Pacific Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 49. Asia-Pacific Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 50. Asia-Pacific Neuroblastoma Drugs Market, by Country, 2022-2032 ($Million)
Table 51. Japan Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 52. Japan Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 53. Japan Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 54. China Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 55. China Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 56. China Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 57. India Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 58. India Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 59. India Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 60. Australia Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 61. Australia Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 62. Australia Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 63. South Korea Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 64. South Korea Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 65. South Korea Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 66. Rest of Asia-Pacific Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 67. Rest of Asia-Pacific Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 68. Rest of Asia-Pacific Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 69. LAMEA Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 70. LAMEA Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 71. LAMEA Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 72. LAMEA Neuroblastoma Drugs Market, by Country, 2022-2032 ($Million)
Table 73. Brazil Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 74. Brazil Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 75. Brazil Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 76. Saudi Arabia Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 77. Saudi Arabia Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 78. Saudi Arabia Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 79. South Africa Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 80. South Africa Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 81. South Africa Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 82. Rest of LAMEA Neuroblastoma Drugs Market, by Type, 2022-2032 ($Million)
Table 83. Rest of LAMEA Neuroblastoma Drugs Market, by Route of Administration, 2022-2032 ($Million)
Table 84. Rest of LAMEA Neuroblastoma Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 85. Recordati Group: Key Executives
Table 86. Recordati Group: Company Snapshot
Table 87. Recordati Group: Product Segments
Table 88. Recordati Group: Product Portfolio
Table 89. Recordati Group: Key Strategies
Table 90. Astrazeneca PLC: Key Executives
Table 91. Astrazeneca PLC: Company Snapshot
Table 92. Astrazeneca PLC: Product Segments
Table 93. Astrazeneca PLC: Product Portfolio
Table 94. Bristol-Myers Squibb Company: Key Executives
Table 95. Bristol-Myers Squibb Company: Company Snapshot
Table 96. Bristol-Myers Squibb Company: Product Segments
Table 97. Bristol-Myers Squibb Company: Product Portfolio
Table 98. Cellectar Biosciences, Inc.: Key Executives
Table 99. Cellectar Biosciences, Inc.: Company Snapshot
Table 100. Cellectar Biosciences, Inc.: Product Segments
Table 101. Cellectar Biosciences, Inc.: Product Portfolio
Table 102. Eli Lilly and Company: Key Executives
Table 103. Eli Lilly and Company: Company Snapshot
Table 104. Eli Lilly and Company: Product Segments
Table 105. Eli Lilly and Company: Product Portfolio
Table 106. Macrogenics Inc.: Key Executives
Table 107. Macrogenics Inc.: Company Snapshot
Table 108. Macrogenics Inc.: Product Segments
Table 109. Macrogenics Inc.: Product Portfolio
Table 110. Pfizer Inc.: Key Executives
Table 111. Pfizer Inc.: Company Snapshot
Table 112. Pfizer Inc.: Product Segments
Table 113. Pfizer Inc.: Product Portfolio
Table 114. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 115. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 116. Teva Pharmaceutical Industries Ltd.: Product Segments
Table 117. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 118. United Therapeutics Corporation: Key Executives
Table 119. United Therapeutics Corporation: Company Snapshot
Table 120. United Therapeutics Corporation: Product Segments
Table 121. United Therapeutics Corporation: Product Portfolio
Table 122. United Therapeutics Corporation: Key Strategies
Table 123. Y-Mabs Therapeutics, Inc.: Key Executives
Table 124. Y-Mabs Therapeutics, Inc.: Company Snapshot
Table 125. Y-Mabs Therapeutics, Inc.: Product Segments
Table 126. Y-Mabs Therapeutics, Inc.: Product Portfolio
Table 127. Y-Mabs Therapeutics, Inc.: Key Strategies
List of Figures
Figure 01. Neuroblastoma Drugs Market, 2022-2032
Figure 02. Segmentation of Neuroblastoma Drugs Market,2022-2032
Figure 03. Top Impacting Factors in Neuroblastoma Drugs Market (2022 to 2032)
Figure 04. Top Investment Pockets in Neuroblastoma Drugs Market (2023-2032)
Figure 05. Moderate Bargaining Power of Suppliers
Figure 06. Moderate Threat of New Entrants
Figure 07. Moderate Threat of Substitutes
Figure 08. Moderate Intensity of Rivalry
Figure 09. Moderate Bargaining Power of Buyers
Figure 10. Global Neuroblastoma Drugs Market:Drivers, Restraints and Opportunities
Figure 11. Neuroblastoma Drugs Market, by Type, 2022 and 2032(%)
Figure 12. Comparative Share Analysis of Neuroblastoma Drugs Market for Chemotherapy, by Country 2022 and 2032(%)
Figure 13. Comparative Share Analysis of Neuroblastoma Drugs Market for Immunotherapy, by Country 2022 and 2032(%)
Figure 14. Comparative Share Analysis of Neuroblastoma Drugs Market for Others, by Country 2022 and 2032(%)
Figure 15. Neuroblastoma Drugs Market, by Route of Administration, 2022 and 2032(%)
Figure 16. Comparative Share Analysis of Neuroblastoma Drugs Market for Oral, by Country 2022 and 2032(%)
Figure 17. Comparative Share Analysis of Neuroblastoma Drugs Market for Injectable, by Country 2022 and 2032(%)
Figure 18. Neuroblastoma Drugs Market, by Distribution Channel, 2022 and 2032(%)
Figure 19. Comparative Share Analysis of Neuroblastoma Drugs Market for Online, by Country 2022 and 2032(%)
Figure 20. Comparative Share Analysis of Neuroblastoma Drugs Market for Offline, by Country 2022 and 2032(%)
Figure 21. Neuroblastoma Drugs Market by Region, 2022 and 2032(%)
Figure 22. U.S. Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 23. Canada Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 24. Mexico Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 25. Germany Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 26. France Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 27. UK Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 28. Italy Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 29. Spain Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 30. Rest of Europe Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 31. Japan Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 32. China Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 33. India Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 34. Australia Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 35. South Korea Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 36. Rest of Asia-Pacific Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 37. Brazil Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 38. Saudi Arabia Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 39. South Africa Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 40. Rest of LAMEA Neuroblastoma Drugs Market, 2022-2032 ($Million)
Figure 41. Top Winning Strategies, by Year (2020-2023)
Figure 42. Top Winning Strategies, by Development (2020-2023)
Figure 43. Top Winning Strategies, by Company (2020-2023)
Figure 44. Product Mapping of Top 10 Players
Figure 45. Competitive Dashboard
Figure 46. Competitive Heatmap: Neuroblastoma Drugs Market
Figure 47. Top Player Positioning, 2022
Figure 48. Recordati Group: Net Revenue, 2020-2022 ($Million)
Figure 49. Recordati Group: Revenue Share by Segment, 2022 (%)
Figure 50. Recordati Group: Revenue Share by Region, 2022 (%)
Figure 51. Astrazeneca PLC: Net Revenue, 2020-2022 ($Million)
Figure 52. Astrazeneca PLC: Revenue Share by Region, 2022 (%)
Figure 53. Bristol-Myers Squibb Company: Net Revenue, 2020-2022 ($Million)
Figure 54. Bristol-Myers Squibb Company: Revenue Share by Region, 2022 (%)
Figure 55. Eli Lilly and Company: Net Revenue, 2020-2022 ($Million)
Figure 56. Eli Lilly and Company: Revenue Share by Region, 2022 (%)
Figure 57. Macrogenics Inc.: Net Revenue, 2020-2022 ($Million)
Figure 58. Pfizer Inc.: Net Revenue, 2020-2022 ($Million)
Figure 59. Pfizer Inc.: Revenue Share by Segment, 2022 (%)
Figure 60. Pfizer Inc.: Revenue Share by Region, 2022 (%)
Figure 61. Teva Pharmaceutical Industries Ltd.: Net Revenue, 2020-2022 ($Million)
Figure 62. Teva Pharmaceutical Industries Ltd.: Revenue Share by Segment, 2022 (%)
Figure 63. Teva Pharmaceutical Industries Ltd.: Revenue Share by Region, 2022 (%)
Figure 64. United Therapeutics Corporation: Net Sales, 2020-2022 ($Million)
Figure 65. United Therapeutics Corporation: Revenue Share by Region, 2022 (%)
Figure 66. Y-Mabs Therapeutics, Inc.: Net Revenue, 2020-2022 ($Million)